



65 West Watkins Mill Road
Gaithersburg, MD 20878
tel: 240-632-0740
fax: 240-632-0735
www.genvec.com

FOR IMMEDIATE RELEASE

CONTACT:

Sharon L. Weinstein
Director, Investor Relations
and Corporate Communications
(240) 632-5511
sweinstein@genvec.com

GENVEC ANNOUNCES SECOND QUARTER 2007 RESULTS CONFERENCE CALL

GAITHERSBURG, MD – July 31, 2007 – GenVec, Inc. (Nasdaq:GNVC) will hold a conference call on Tuesday, August 7, 2007 at 4:30 p.m. ET (1:30 p.m. PT) to discuss the results for the second quarter ended June 30, 2007. The results are expected to be released at 8:30 a.m. ET that same morning.

Dr. Paul H. Fischer, GenVec's President and Chief Executive Officer, will host the call. To listen to the live conference call, please dial 888.680.0878 (U.S. or Canada) or 617.213.4855 (international) and use access code 31299753. Investors interested in registering for the conference call and webcast in advance may log on to: <https://www.theconferencingservice.com/prereg/key.process?key=RMTUJ6XE4>

An audio replay of the conference call will be available starting at 6:30 p.m. on August 7, 2007 through August 14, 2007. To listen to the audio replay, dial 888.286.8010 (U.S. or Canada) or 617.801.6888 (international) and use access code 76302471.

A live webcast of the conference call will be available in listen only mode on the Company's web site at www.genvec.com and archived for 30 days. To access the webcast or the replay, go to the "Investor Relations" page and click on the link to the Webcasts and Data section.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade™ is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

###